Differential signaling in response to glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) stimulation in the vasculature: modulation of osteopontin expression

被引：0

作者：

Berglund, Lisa M. ^{[1
]}

Lyssenko, Valeriya ^{[1
]}

Kotova, Olga ^{[1
]}

Zetterqvist, Anna V. ^{[1
]}

Gottsater, Anders ^{[1
]}

Vaag, Allan ^{[2
]}

Goncalves, Isabel ^{[1
]}

Groop, Leif ^{[1
]}

Gomez, Maria F. ^{[1
]}

机构：

[1] Lund Univ, Malmo, Sweden

[2] Steno Diabet Ctr, DK-2820 Gentofte, Denmark

来源：

FASEB JOURNAL | 2011年 / 25卷

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页数：1

共 50 条

[1] Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Bulum, Tomislav
BIOMEDICINES, 2022, 10 (10)
[2] Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today: Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP)
Kiec-Klimczak, Malgorzata E.
Pach, Dorota M.
Pogwizd, Magdalena E.
Hubalewska-Dydejczyk, Alicja B.
RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2011, 5 (03) : 176 - 182
[3] Both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) contributes to the insulinotropic effect at basal and postprandial glucose levels in healthy subjects
Krarup, T
Vilsboll, T
Madsbad, S
Holst, JJ
DIABETOLOGIA, 2003, 46 : A201 - A201
[4] Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits
Gjesing, A. P.
Ekstrom, C. T.
Eiberg, H.
Urhammer, S. A.
Holst, J. J.
Pedersen, O.
Hansen, T.
DIABETOLOGIA, 2012, 55 (05) : 1338 - 1345
[5] The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
Fisman, Enrique Z.
Tenenbaum, Alexander
CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
[6] Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits
A. P. Gjesing
C. T. Ekstrøm
H. Eiberg
S. A. Urhammer
J. J. Holst
O. Pedersen
T. Hansen
Diabetologia, 2012, 55 : 1338 - 1345
[7] The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
Enrique Z. Fisman
Alexander Tenenbaum
Cardiovascular Diabetology, 20
[8] Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes
Frias, Juan P.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2020, 15 (06) : 379 - 394
[9] Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1)
Ranganath, L
Schaper, F
Gama, R
Morgan, L
Wright, J
Teale, D
Marks, V
DIABETES-METABOLISM RESEARCH AND REVIEWS, 1999, 15 (06) : 390 - 394
[10] Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypcptide (GIP) as future antidiabetic agents
Green, BD
Gault, VA
O'Harte, FPM
Flatt, PR
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (29) : 3651 - 3662

← 1 2 3 4 5 →